

November 8, 2007

Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case

Tokyo, Japan and Ridgefield, CT, November 8, 2007 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) and Boehringer Ingelheim Pharmaceuticals, Inc. (headquarters: Ridgefield, a subsidiary of Boehringer Ingelheim Corporation (headquarters: Germany)) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to US Patent No. 4,703,063 for Flomax[®] (generic name: tamsulosin HCl capsules, brand name in Japan: Harnal[®]), a treatment for the functional symptoms of benign prostatic hyperplasia.

As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com